CYCN
Cyclerion Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$15.16M
P/E Ratio
—
EPS
$-1.31
Beta
1.75
52W High
$8.48
52W Low
$1.03
50-Day MA
$3.33
200-Day MA
$2.28
Dividend Yield
—
Profit Margin
-264.70%
Forward P/E
—
PEG Ratio
—
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.99M |
| Gross Profit (TTM) | 340,000 |
| EBITDA | $-9.58M |
| Operating Margin | -337.40% |
| Return on Equity | -67.80% |
| Return on Assets | -45.80% |
| Revenue/Share (TTM) | $0.56 |
| Book Value | $1.60 |
| Price-to-Book | 2.23 |
| Price-to-Sales (TTM) | 7.60 |
| EV/Revenue | 6.19 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -43.20% |
| Shares Outstanding | $4.33M |
| Float | $3.14M |
| % Insiders | 21.02% |
| % Institutions | 3.99% |
Historical Volatility
HV 10-Day
23.85%
HV 20-Day
50.31%
HV 30-Day
47.24%
HV 60-Day
40.28%
HV Rank
—
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CYCN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026